Biotechs are some of the riskiest -- and sometimes the most rewarding -- investments around, and for good reason. Buying a stock in a totally unproven company that doesn't even have a product or any revenue means taking on a lot of uncertainty, both for good and for ill. Making a move before anyone else can see the value in a company's therapy candidate isn't an exact science, and investors need at least a little bit of luck along the way if they're going to get rich.
Celldex Therapeutics (NASDAQ: CLDX) is developing immunotherapeutic antibodies that could one day be used to treat seemingly intractable diseases like metastatic pancreatic cancer and urticaria. The company's efforts are just getting started, and it must complete a marathon of clinical trials in the years ahead before it can hope to report any earnings. But that's exactly what could give this stock the potential to make millions for people who buy it at the right time.
Image source: Getty Images
For further details see:
Could Celldex Be a Millionaire-Maker Stock?